Author

Johanna MGH van Riel

Observed names: Johanna MG Van Riel, Johanna MGH Van Riel

Observed institution: Elisabeth-TweeSteden Ziekenhuis

OpenAlex ID: A5000717457

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

2018 · Annemieke Cats, Edwin P M Jansen, et al. · The Lancet Oncology · 565

Circulating tumor DNA dynamics in resectable gastric cancer.

2018 · Alessandro Leal, Nicole C.T. van Grieken, et al. · Journal of Clinical Oncology · 2

Abstract P6-08-09: Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients

2015 · Siu W Lam, Charlotte N Frederiks, et al. · Cancer Research · 1

Abstract P3-06-09: Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)

2015 · Siu W Lam, Nienke M Nota, et al. · Cancer Research · 1

A real-world study on implementation of new therapeutic options, especially bevacizumab, in a cohort of HER2-negative metastatic breast cancer patients treated with first-line chemotherapy.

2013 · Roel JW Van Kampen, Dorien JA Lobbezoo, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 569

H-index: 2

I10-index: 1